Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.66B P/E - EPS this Y -5.90% Ern Qtrly Grth -
Income -559M Forward P/E 3.78 EPS next Y 9.50% 50D Avg Chg 19.00%
Sales 15.85B PEG 3.34 EPS past 5Y 1.90% 200D Avg Chg 4.00%
Dividend N/A Price/Book 1.32 EPS next 5Y 1.60% 52W High Chg -19.00%
Recommedations 2.40 Quick Ratio 0.54 Shares Outstanding 1.13B 52W Low Chg 30.00%
Insider Own - ROA 4.54% Shares Float 1.11B Beta 1.06
Inst Own 52.65% ROE -7.36% Shares Shorted/Prior 11.56M/14.72M Price 9.25
Gross Margin 48.25% Profit Margin -3.53% Avg. Volume 14,211,503 Target Price 15.50
Oper. Margin 28.05% Earnings Date - Volume 32,973,594 Change 11.58%
About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Teva Pharmaceutical Industries News
04/22/24 UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
04/21/24 11 Best Low Price Pharma Stocks To Invest In
04/19/24 Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
04/18/24 3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
04/16/24 Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
04/16/24 Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
04/15/24 Israeli economy has proven to thrive despite crisis: Expert
04/11/24 Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
04/09/24 Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
04/06/24 New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
04/04/24 Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
04/03/24 3 No-Brainer Stocks to Buy With $600 Right Now
04/03/24 Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers
04/01/24 UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
04/01/24 Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
04/01/24 Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
03/28/24 Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?
03/26/24 Institutional investors have a lot riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 67% ownership
03/25/24 Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
06:30 PM 25 Countries with the Lowest Fertility Rates
TEVA Chatroom

User Image NNJAWINLIVE Posted - 9 hours ago

$TEVA

User Image TheDudeRooster Posted - 13 hours ago

$TEVA Watching out for a Falling Three Methods continuation pattern. Fingers crossed Raymond James continues to aggressively add. Guess we can assume who owns the 13's lol.

User Image TheDudeRooster Posted - 16 hours ago

$TEVA

User Image DonCorleone77 Posted - 1 day ago

$VNDA $TEVA Vanda Pharmaceuticals responds to U.S. Supreme Court denial of petition Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."

User Image Terrordomo80 Posted - 1 day ago

$TEVA 13 now be like...

User Image NNJAWINLIVE Posted - 1 day ago

$TEVA niceeee pop it

User Image NNJAWINLIVE Posted - 1 day ago

$TEVA long term hold

User Image Terrordomo80 Posted - 1 day ago

$TEVA what crap!

User Image Hopewisper Posted - 4 days ago

$TEVA I see growth on the horizon

User Image Aigner_Andreas Posted - 4 days ago

TD BUY $TEVA at 12.86, Supp 12.78 Resis 14.25 R12 HiLo 78% T1Y 10 hold 3.0 DIV N/A #Teva Pharm #stocks #trading #finance #market

User Image NNJAWINLIVE Posted - 4 days ago

$TEVA bought dipp

User Image TheDudeRooster Posted - 4 days ago

$TEVA I’d rather take my lumps and wait out the gap than add-on now that could help bail them out. Left us out here taking grenades, but now there’s an urgency.

User Image Sdotrayborn Posted - 4 days ago

$TEVA it’s literally doing what it did after October 7th with a gap on August 2nd that it filled and people are crying lol. Plz give us a juicy big red candle on Monday and let’s get this show on the road!

User Image Sdotrayborn Posted - 4 days ago

$TEVA never wanted a gap fill so bad let’s go get it over with

User Image Terrordomo80 Posted - 4 days ago

$TEVA Even $ALVO is now outperforming us.. Doc Jizzards be like...

User Image TheDudeRooster Posted - 4 days ago

$TEVA For the genius that transferred all those 6/21 12.0's to 13.0's for a better delta now combating a short block algo

User Image Terrordomo80 Posted - 4 days ago

$TEVA pos struggling to crack 13 now...

User Image TheDudeRooster Posted - 4 days ago

$TEVA Dueling algos

User Image TheDudeRooster Posted - 4 days ago

$TEVA Desperate 13.0 strike OTM pump. It will be interesting to see what they do when they get there.

User Image NNJAWINLIVE Posted - 4 days ago

$TEVA nice dippp! Bought it

User Image G101SPM Posted - 4 days ago

$TEVA $12.72 bid. DAC $12.00 (1.31.24). EXIT $19.00. UPDATE: Alvotech(ALVO) said Friday that it has signed a long-term agreement with an unidentified partner to expand access to Adalimumab-ryvk, a biosimilar to Abbvie's(ABBV) drug Humira, in the US; existing multiproduct commercialization partnership with Teva Pharmaceutical (TEVA) will remain unchanged and that Teva will continue to commercialize Adalimumab-ryvk in the US under the Simlandi brand.

User Image DonCorleone77 Posted - 5 days ago

$ALVO $TEVA Alvotech signs agreement with Teva to bring Adalimumab-ryvk to U.S. market Alvotech (ALVO) announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly FDA approved high-concentration interchangeable biosimilar to Humira. The current multi-product commercialization partnership between Teva Pharmaceuticals (TEVA) and Alvotech remains unchanged and Teva will continue to commercialize adalimumab-ryvk under the Simland brand in the U.S.

User Image Terrordomo80 Posted - 5 days ago

$TEVA

User Image Hopewisper Posted - 5 days ago

$TEVA Might fall more.... but it's....

User Image Aigner_Andreas Posted - 5 days ago

TF SELL $TEVA at 12.78 : 12.97 BigCap 98% Shp 2.61 S 4.92 N 1.14 RSI 34.53% SRSI 0% ADXR 27.14 #stocks #trading #finance #market

User Image TheDudeRooster Posted - 5 days ago

$TEVA Might as well fill or partially fill the gap now. Let’s get the beatdown over with.

User Image Terrordomo80 Posted - 5 days ago

$TEVA The bottom is this folks whether you realize it or not... There's zero reason why TEVA should be continually dropping day after day bleeding out in an environment where the overall mkt is realizing the fact rate cuts aren't happening this year and inflation will continue to increase longer than most had anticipated...If anything the Fed may need to hike rates once or twice more before all is said and done...But this shouldn't be affecting TEVAs business is should be enabling it... So the obvious is showing itself as always...They kept TEVA propped up as the mkt began to fall and as always in the end it is now falling in line with the mkt as it catches up and burns out all the call buyers and hopeful Bulls here... the greatest part for the mkt maker and Wall St is they can take this to wherever they desire now as this descending slope continues to get steeper and pick up speed...

User Image Longaeva_Capital Posted - 5 days ago

$TEVA unfortunately it looks like we are going to fill the gap

User Image Sdotrayborn Posted - 5 days ago

$TEVA all I ask is make it quick to 12 none of this slow bleeding plz

User Image Terrordomo80 Posted - 5 days ago

$TEVA

Analyst Ratings
JP Morgan Neutral Mar 8, 24
Piper Sandler Overweight Feb 12, 24
Goldman Sachs Neutral Feb 5, 24
Barclays Overweight Feb 5, 24
Barclays Overweight Jan 29, 24
Jefferies Buy Jan 23, 24
Piper Sandler Neutral Jan 3, 24
HSBC Buy Dec 18, 23
UBS Buy Nov 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Weiss Amir Chief Accounting Off.. Chief Accounting Officer Feb 01 Sell 12.3703 31,766 392,955 10,676 02/05/24
Hughes Eric A See "Remarks" See "Remarks" Aug 01 Sell 8.3 52,742 437,759 08/03/23
Kalif Eliyahu Sharon EVP, Chief Financial.. EVP, Chief Financial Officer Aug 22 Sell 10.0666 55,500 558,696 9,376 08/24/22
Stark David Matthew Exec. VP Chief Legal.. Exec. VP Chief Legal Officer Jul 28 Sell 9.0365 58,163 525,590 2,974 07/29/22
Fridriksdottir Hafrun Executive VP, Global.. Executive VP, Global R&D May 17 Sell 8.2159 130,000 1,068,067 1,387 05/19/22
Drape Eric Executive VP Global.. Executive VP Global Operations Mar 04 Sell 7.44 34,792 258,852 78,072 03/08/22
Dethlefs Sven EVP, North America C.. EVP, North America Commercial Mar 04 Sell 7.42 10,897 80,856 165,381 03/08/22
Daniell Richard Exec. VP, European C.. Exec. VP, European Commercial Mar 04 Sell 7.44 58,952 438,603 43,182 03/08/22
Stark David Matthew Exec. VP Chief Legal.. Exec. VP Chief Legal Officer Feb 28 Sell 8.14 6,452 52,519 21,380 03/02/22
Shani Eli EVP,Global Marketing.. EVP,Global Marketing&Portfolio Feb 28 Sell 8.14 5,311 43,232 9,091 03/02/22
Fridriksdottir Hafrun Executive VP, Global.. Executive VP, Global R&D Feb 28 Sell 8.14 7,590 61,783 65,509 03/02/22
Drape Eric Executive VP Global.. Executive VP Global Operations Feb 28 Sell 8.14 9,797 79,748 45,830 03/02/22
Dethlefs Sven EVP, North America C.. EVP, North America Commercial Feb 28 Sell 8.14 4,862 39,577 99,457 03/02/22
Daniell Richard Exec. VP, European C.. Exec. VP, European Commercial Feb 28 Sell 8.14 20,598 167,668 20,280 03/02/22
Stark David Matthew Exec. VP Chief Legal.. Exec. VP Chief Legal Officer Feb 08 Sell 9.06 6,110 55,357 9,402 02/10/22
Stark David Matthew Exec. VP Chief Legal.. Exec. VP Chief Legal Officer May 13 Sell 10.22 37,884 387,174 2,974 05/13/21
Drape Eric Executive VP Global.. Executive VP Global Operations May 13 Sell 10.22 19,804 202,397 73,128 05/13/21
Nazzi Gianfranco EVP, International M.. EVP, International Markets Mar 08 Sell 10.58 12,935 136,852 03/08/21
Drape Eric Executive VP Global.. Executive VP Global Operations Mar 08 Sell 10.58 6,183 65,416 55,048 03/08/21
Dethlefs Sven EVP Global Marketing.. EVP Global Marketing&Portfolio Mar 08 Sell 10.57 6,012 63,547 77,976 03/08/21
Nazzi Gianfranco EVP, International M.. EVP, International Markets Mar 04 Sell 10.88 1,400 15,232 03/04/21
Fridriksdottir Hafrun Executive VP, Global.. Executive VP, Global R&D Feb 17 Sell 11.12 2,098 23,330 103,294 02/17/21
O'Grady Brendan P. EVP, North America C.. EVP, North America Commercial Feb 11 Sell 12.69 20,694 262,607 78,146 02/11/21
Dethlefs Sven EVP Global Marketing.. EVP Global Marketing&Portfolio Feb 11 Sell 12.69 29,657 376,347 59,404 02/11/21
Daniell Richard Exec. VP, European C.. Exec. VP, European Commercial Sep 10 Sell 8.98 333 2,990 10,765 09/10/20